Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-57P (RNA, U4 small nuclear 57, pseudogene) is classified as a pseudogene in the human genome. It is a predicted or annotated copy of the gene encoding U4 small nuclear RNA (snRNA), an essential component of the major spliceosome complex required for pre-mRNA splicing in eukaryotes[3][5][7]. Unlike the functional RNU4-2 gene, which encodes U4 snRNA and is implicated in neurodevelopmental disorders (such as ReNU syndrome) when mutated[3][5][6][7], pseudogene copies like RNU4-57P are generally regarded as non-functional. They do not produce an active RNA molecule and have not been shown to play a role in normal biology, disease, drug interaction, or serve as therapeutic or diagnostic markers. **Notes on correctness:** - **is_incorrect:** true, because RNU4-57P is a pseudogene and NOT a canonical, functional spliceosome component or molecular target; there are no known biological activities, disease associations, or drugs targeting this pseudogene. Many similar pseudogenes for U4 snRNA (e.g., RNU4-52P, RNU4-78P) exist, and functional information pertains to RNU4-2 or RNU4-1 genes, not to pseudogenes[2][1]. - Functional and disease associations detailed in research apply to *functional U4 snRNA genes* (notably RNU4-2), which are critical for splicing and display dominant or recessive pathogenic variants involved in neurodevelopmental disorders[3][5][6][7]. These findings do NOT pertain to RNU4-57P or other pseudogenes. **Summary of classification:** - RNU4-57P is a **pseudogene** of U4 snRNA, not a protein, receptor, enzyme, or transporter. - No biological function, disease involvement, or drug interactions are known for RNU4-57P. - If your goal is to identify therapeutic or biological targets, *refer to the functional U4 snRNA genes (RNU4-2, RNU4-1)*, not their pseudogenes[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 57, pseudogene (RNU4-57P).